Table 1 Patient demographic and clinical characteristics
TTP (N = 463) | PPP (N = 439) | |
|---|---|---|
Age, years, mean (SD) | 32.2 (4.1) | 32.1 (4.0) |
BMI, kg/m2, mean (SD) | 23.4 (3.6) | 23.3 (3.2) |
AMH, ng/mL, mean (SD) | 3.6 (2.3) | 3.6 (2.3) |
Total r-hFSH dose, IU | ||
Mean (SD) | 1651.2 (506.7) | 1629.4 (479.9) |
Median | 1516.0 | 1500.0 |
Range | 750.0–3825.0 | 750.0–3825.0 |
Duration of FSH stimulation, days | ||
Mean (SD) | 9.5 (1.7) | 9.5 (1.7) |
Median | 9.0 | 9.0 |
Range | 4.0–17.0 | 5.0–16.0 |
GnRH antagonist protocol | ||
Missing, n (%) | 1 (0.2) | 0 |
No GnRH antagonist used, n (%) | 8 (1.7) | 0 |
Cetrorelix, n (%) | 116 (25.1) | 115 (26.2) |
Days, mean (SD) | 6.2 (1.9) | 6.3 (1.9) |
Ganirelix, n (%) | 338 (73.0) | 324 (73.8) |
Days, mean (SD) | 5.0 (1.7) | 5.0 (1.7) |
Serum estradiol prior to trigger, ng/L, mean (SD) | 1362.0 (969.5) | 1380.6 (968.8) |
Endometrial thickness prior to trigger, mm, mean (SD) | 9.7 (2.0) | 9.8 (2.0) |
Used for follicular maturation triggering | ||
Missing, n (%) | 8 (1.7) | 6 (1.4) |
Recombinant hCG, n (%) | 196 (42.3) | 183 (41.7) |
Urinary hCG, n (%) | 198 (42.8) | 190 (43.3) |
GnRH agonist, n (%) | 61 (13.2) | 60 (13.7) |